Abcellera Biologics Inc (ABCL) - Net Assets
Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has net assets worth $1.14 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.36 Billion) and total liabilities ($215.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ABCL asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.14 Billion |
| % of Total Assets | 84.11% |
| Annual Growth Rate | 92.59% |
| 5-Year Change | 11.27% |
| 10-Year Change | N/A |
| Growth Volatility | 2798.3 |
Abcellera Biologics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's net assets have evolved over time, based on quarterly financial data. Also explore ABCL current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Abcellera Biologics Inc (2018–2025)
The table below shows the annual net assets of Abcellera Biologics Inc from 2018 to 2025. For live valuation and market cap data, see Abcellera Biologics Inc (ABCL) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.14 Billion | +8.07% |
| 2024-12-31 | $1.06 Billion | -8.35% |
| 2023-12-31 | $1.15 Billion | -6.56% |
| 2022-12-31 | $1.23 Billion | +20.23% |
| 2021-12-31 | $1.03 Billion | +23.51% |
| 2020-12-31 | $830.51 Million | +8000.94% |
| 2019-12-31 | $10.25 Million | -11.69% |
| 2018-12-31 | $11.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abcellera Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2697706400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $802.34 Million | 70.30% |
| Other Comprehensive Income | $-4.23 Million | -0.37% |
| Other Components | $372.73 Million | 32.66% |
| Total Equity | $1.14 Billion | 100.00% |
Abcellera Biologics Inc Competitors by Market Cap
The table below lists competitors of Abcellera Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SHOP APOTH. UNSP.ADR/010
F:SAE1
|
$1.07 Billion |
|
Fiskars Oyj Abp
HE:FSKRS
|
$1.07 Billion |
|
Shenzhen Bromake New Material Co. Ltd. A
SHE:301387
|
$1.07 Billion |
|
Shenzhen Chuangyitong Technology Co.Ltd.
SHE:300991
|
$1.07 Billion |
|
Brighton-Best International Taiwan
TWO:8415
|
$1.07 Billion |
|
Newonder Special Electric Co.Ltd
SHE:301120
|
$1.07 Billion |
|
MAGYAR TELE.A ADR/5 UF100
F:MGYA
|
$1.07 Billion |
|
Jintuo Technology Co Ltd
SHG:603211
|
$1.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abcellera Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,056,084,000 to 1,141,357,000, a change of 85,273,000 (8.1%).
- Net loss of 146,412,000 reduced equity.
- Other comprehensive income increased equity by 144,000.
- Other factors increased equity by 231,541,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-146.41 Million | -12.83% |
| Other Comprehensive Income | $144.00K | +0.01% |
| Other Changes | $231.54 Million | +20.29% |
| Total Change | $- | 8.07% |
Book Value vs Market Value Analysis
This analysis compares Abcellera Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 57.63x to 1.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.08 | $4.43 | x |
| 2019-12-31 | $0.04 | $4.43 | x |
| 2020-12-31 | $3.16 | $4.43 | x |
| 2021-12-31 | $3.22 | $4.43 | x |
| 2022-12-31 | $3.92 | $4.43 | x |
| 2023-12-31 | $3.98 | $4.43 | x |
| 2024-12-31 | $3.59 | $4.43 | x |
| 2025-12-31 | $3.82 | $4.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abcellera Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -194.88%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.19x
- Recent ROE (-12.83%) is below the historical average (-4.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 2.66% | 3.50% | 0.41x | 1.85x | $-851.92K |
| 2019 | -21.57% | -19.04% | 0.49x | 2.29x | $-3.24 Million |
| 2020 | 14.32% | 51.00% | 0.23x | 1.21x | $35.87 Million |
| 2021 | -0.22% | -19.04% | 0.01x | 1.29x | $-104.78 Million |
| 2022 | 12.85% | 32.66% | 0.32x | 1.25x | $35.19 Million |
| 2023 | -12.70% | -385.00% | 0.03x | 1.29x | $-261.63 Million |
| 2024 | -15.42% | -564.83% | 0.02x | 1.29x | $-268.47 Million |
| 2025 | -12.83% | -194.88% | 0.06x | 1.19x | $-260.55 Million |
Industry Comparison
This section compares Abcellera Biologics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $147,732,594
- Average return on equity (ROE) among peers: -131.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | 2.66% | 0.19x | $1.07 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more